12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Company News  |  Deals

Cara, Chong Kun Dang deal

Cara granted Chong Kun Dang exclusive rights in South Korea to develop and commercialize pain therapy CR845. Cara will...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >